Investors angry about insulin woes sue Novo Nordisk in Denmark for $1.75B

artist rendering
Novo faces a new investor lawsuit in Denmark seeking $1.75 billion in damages. (Novo Nordisk)

Novo’s been relying less on insulins for growth these days as its GLP-1 franchise steams ahead. But trouble in its insulin franchise still lingers—and now it'll have to defend against a group of investors who sued in Denmark, claiming it made “misleading” statements about its insulin sales.

And the investors want payback—in a big way. They're demanding about $1.75 billion in compensation.

The shareholder lawsuit claims losses from February 2015 to February 2017 based on allegations the company misled the public about its insulin sales in the U.S. The drugmaker said the complaint “appears to contain broadly similar allegations to those of the previously announced securities class-action lawsuit” filed in the U.S. in 2017.


Bioavailability Enhancement – Industry Insights, Key Challenges & Advanced Development Solutions

Join this webcast on Tuesday, June 16 as experts present the exclusive survey findings and introduce innovative scalable drug delivery technologies proven to address the industry’s growing need for improving solubility and enhancing bioavailability.

Novo hit back that it “disagrees with the allegations and is prepared to defend the company in this matter.”

Insulin makers have faced years of allegations, criticism and investigations over their prices, even as sales have fallen. In the U.S., list prices have climbed in recent years, as have rebates to pharma middlemen. That dynamic has led patients to pay more for their medicines, while drugmakers have reported flat or declining net sales.

RELATED: Amid insulin market scrutiny, Novo faces class action alleging 'collusive price fixing'

A group of Novo investors sued the drugmaker back in early 2017 alleging the company “misrepresented and concealed the true extent” of insulin pricing pressure from payers. Aside from investor suits, states have sued insulin makers for violations of consumer protection laws and deceptive pricing.

Amid its insulin pricing squeeze, Novo has pivoted toward its GLP-1 franchise, hoping to rely less on the insulins for growth. In the first half of the year, the company's group of GLP-1 diabetes and obesity meds fueled growth at the drugmaker, bringing in $2.63 billion, a 29% increase. The company also hopes to win a highly anticipated approval for oral semaglutide yet this year.

Suggested Articles

A new NEJM study found taking hydroxychloroquine after COVID-19 exposure doesn't reduce the risk of an infection. But questions remain.

Novartis is touting 52-week data for Cosentyx in spondyloarthritis––an indication where Eli Lilly's Taltz recently scored a trailblazing FDA approval.

Gilead's remdesivir could bring in $7.6 billion in sales in 2022 and a decent profit margin, SVB Leerink predicted, but there are caveats.